Shares of Enanta Pharmaceuticals have surged heading in a pivotal regulatory review of the company’s lead hepatitis C therapy. Short-sellers apparently don’t share the market’s outlook and have started moving into the stock. Should you be worried?
Shares of Enanta Pharmaceuticals have surged heading in a pivotal regulatory review of the company’s lead hepatitis C therapy. Short-sellers apparently don’t share the market’s outlook and have started moving into the stock. Should you be worried?